搜索
请登录
提醒成功
微信/QQ登录
搜索
首页
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00049 |
| Application | Flow cytometry, animal model study |
| Aliases | B-lymphocyte antigen CD20, MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human CD20 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Obinutuzumab Biosimilar uses the same protein sequences as the therapeutic antibody obinutuzumab. Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies. |
Obinutuzumab Biosimilar, CD20 Monoclonal Antibody B00049
规格：
- 1mg
- 5mg
- 20mg
数量：
-
+
说明书：
¥1300
-
分享
-
咨询
-
收藏
联系方式
CONTACT-
联系电话:
0731-88388787 -
公司邮箱:
sales@promab.cn -
公司地址:
湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼
官方微信
产品中心
Product技术服务
service客户留言
message